Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Gabapentin enacarbil (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Acronyms CONCORD
- Sponsors GlaxoSmithKline; GSK; XenoPort
- 10 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Aug 2012 New trial record